Earnings to watch: NeoGenomics (NEO) reports Q3 results tomorrow

What happened

NeoGenomics, an oncology diagnostics company, will report its third-quarter earnings this Wednesday after the market closes. Last quarter it reported revenues of $201.7 million, up 11.2% year on year, and beat analysts' revenue expectations with a narrow beat on full-year earnings-per-share guidance.

Confirmed

Global impact / market context

This report matters because investors can compare actual revenue against the 10.2% growth analysts expect, which is slower than last year's 11.9%. A miss would follow a pattern of past misses, while a beat would support the view that the business is staying on course.

Analyst inference

Peers offer a preview: Quest posted 10% revenue growth and beat estimates by 1%, while Elevance Health reported flat revenue and topped estimates by 3.1%. These results give investors a comparison point for judging whether NeoGenomics' own growth is keeping pace with other healthcare providers.

Analyst inference

What to watch

1. Watch whether reported revenue grows near the 10.2% analysts expect this quarter, versus 11.9% growth recorded in the same quarter last year. Confirmed
2. Compare NeoGenomics' revenue with the $201.7 million reported last quarter and versus analyst expectations. This shows whether its core testing business is expanding or slowing. Proposed
3. Check whether the company beats or misses revenue estimates, since it has missed multiple times over the past two years, which shapes investor confidence in future guidance. Analyst inference

Evidence

• stockstory.org